Should I Buy Pfizer Stock in 2025? Full Irish Market Analysis
Is Pfizer stock a buy right now?
ScorePfizer Inc. (PFE), a giant in the pharmaceutical sector, currently trades around $23.45 with an average daily trading volume of approximately 53.8 million shares (as of late May 2025). Despite a challenging year, with a -11.61% YTD performance primarily due to the normalization of post-pandemic revenues, Pfizer remains a pivotal actor in global healthcare. Its latest quarterly results reflected some revenue declines, but importantly, adjusted earnings per share surpassed expectations, underlining the company’s effective cost-cutting and operational discipline. Noteworthy recent developments include a $6 billion cancer drug licensing deal with 3SBio and a strategic R&D leadership shift, both indicating Pfizer’s commitment to innovation in oncology. While the broader sector faces pressures from global regulatory shifts and fierce competition, sentiment towards Pfizer has turned slightly optimistic, thanks to its robust pipeline and a dividend yield of 7.33% that continues to draw income-focused investors. More than 28 national and international banks converge on a target price of $30.49, underscoring wide analyst confidence in Pfizer’s medium-term recovery and sector leadership. While volatility remains, these factors suggest investors may benefit from considering Pfizer as a core healthcare holding in the current market environment.
- ✅Strong 7.33% dividend yield, well above sector average.
- ✅Robust oncology pipeline, enhanced by recent strategic acquisitions and partnerships.
- ✅Global reach with nearly half of sales generated internationally.
- ✅Solid cash position, supporting further innovation and M&A activity.
- ✅Leader in cost containment with $4.5 billion in savings targeted by end-2025.
- ❌Earnings remain pressured by lower COVID-19 revenues and sector headwinds.
- ❌Ongoing regulatory and competitive challenges could limit short-term growth momentum.
Score- ✅Strong 7.33% dividend yield, well above sector average.
- ✅Robust oncology pipeline, enhanced by recent strategic acquisitions and partnerships.
- ✅Global reach with nearly half of sales generated internationally.
- ✅Solid cash position, supporting further innovation and M&A activity.
- ✅Leader in cost containment with $4.5 billion in savings targeted by end-2025.
Is Pfizer stock a buy right now?
- ✅Strong 7.33% dividend yield, well above sector average.
- ✅Robust oncology pipeline, enhanced by recent strategic acquisitions and partnerships.
- ✅Global reach with nearly half of sales generated internationally.
- ✅Solid cash position, supporting further innovation and M&A activity.
- ✅Leader in cost containment with $4.5 billion in savings targeted by end-2025.
- ❌Earnings remain pressured by lower COVID-19 revenues and sector headwinds.
- ❌Ongoing regulatory and competitive challenges could limit short-term growth momentum.
Score- ✅Strong 7.33% dividend yield, well above sector average.
- ✅Robust oncology pipeline, enhanced by recent strategic acquisitions and partnerships.
- ✅Global reach with nearly half of sales generated internationally.
- ✅Solid cash position, supporting further innovation and M&A activity.
- ✅Leader in cost containment with $4.5 billion in savings targeted by end-2025.
- What is Pfizer?
- How much is the Pfizer stock?
- Our full analysis on the Pfizer stock
- How to buy Pfizer stock in IE?
- Our 7 tips for buying Pfizer stock
- The latest news about Pfizer
- FAQ
What is Pfizer?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | A US-based global pharma leader with a strong international presence. |
| 💼 Market | NYSE | Listed on the New York Stock Exchange, offering high liquidity for investors. |
| 🏛️ ISIN code | US7170811035 | Unique identifier for Pfizer shares traded across global markets. |
| 👤 CEO | Dr. Albert Bourla | Bourla leads a strategic transformation focused on oncology and innovation. |
| 🏢 Market cap | $133.32 billion | Large-cap status supports financial stability and ongoing R&D investments. |
| 📈 Revenue | $62.46 billion (TTM) | Recent revenues declined post-COVID, but core business and pipeline remain resilient. |
| 💹 EBITDA | ~Not specified | Adjusted net income and margins remain stable despite top-line pressure. |
| 📊 P/E Ratio (Price/Earnings) | 16.99 (TTM), 8.03 (forward) | Forward PE signals market expects future earnings growth from new drugs and cost savings. |
How much is the Pfizer stock?
The price of Pfizer stock is rising this week. As of now, Pfizer trades at $23.45, reflecting a 1.16% increase (+$0.27) in the last 24 hours but a small loss of 0.56% for the week. The company holds a market capitalization of $133.32 billion, with an average three-month trading volume of 53.76 million shares. Pfizer’s price/earnings ratio stands at 16.99, offering an attractive dividend yield of 7.33%, and a beta of 0.50 signals low volatility compared to the broader market. For investors in Ireland, this blend of reliable dividends and relative price stability makes Pfizer a noteworthy option for those seeking steady returns amidst global market shifts.
| Metric | Value |
|---|---|
| Current price | $23.45 |
| Change (24h) | +1.16% (+$0.27) |
| Change (week) | -0.56% |
| Market capitalization | $133.32 billion |
| Avg 3-month volume | 53.76 million shares |
| P/E ratio | 16.99 |
| Dividend yield | 7.33% |
| Beta | 0.50 |
Our full analysis on the Pfizer stock
After reviewing Pfizer’s (NYSE: PFE) latest financial results and tracing its share price evolution across the last three years, our analysis—powered by a proprietary blend of financial indicators, technical signals, sector data, and competitive intelligence—identifies key variables with measurable impact on the stock’s future trajectory. Given recent developments in Pfizer’s business fundamentals and the evolving market climate, the question arises: so, why might Pfizer stock once again become a strategic entry point into the pharmaceutical sector in 2025?
Recent Performance and Market Context
Pfizer’s share price currently trades at $23.45 (as of 29 May 2025), sitting near the lower bound of its 52-week range ($20.92–$31.54), a positioning that historically has signalled attractive risk/reward dynamics for long-term investors. While the stock has underperformed the S&P 500 and major pharmaceutical peers over the past twelve months (recording a -16% to -18% decline year-on-year and -11.6% YTD), this period of consolidation is best understood in context: most of the decline is attributable to a post-COVID revenue normalisation phase, not to underlying structural weakness.
Recent quarterly results, while reflecting a 7.8% revenue decrease relative to Q1 2024, showed an adjusted EPS of $0.92—surpassing consensus analyst forecasts—signalling disciplined cost management and operational agility. Notably, the company reaffirmed its 2025 revenue guidance ($61.0–$64.0bn) and an adjusted earnings target of $2.80–$3.00 per share, restoring a tone of measured confidence.
In the broader sector, the confluence of renewed healthcare spending, demographic tailwinds (particularly relevant for Ireland’s ageing population), and robust global drug demand bodes well for pharmaceuticals. Macro trends—including resilient consumer consumption in healthcare, heightened regulatory focus on innovative medicines, and growing international demand—reinforce the case for established, globally active players like Pfizer.
- A $6bn licensing agreement with 3SBio for oncology drug development (May 2025)
- Strategic partnership with Summit Therapeutics leveraging antibody-drug conjugates, highlighting Pfizer’s push into next-gen therapies
- Appointment of Chris Boshoff as Chief Scientific Officer and R&D President—underpinning a renewed drive for scientific innovation
These positive signals, in aggregate, suggest that while the stock price has weathered cyclical pressures, the long-term outlook has strengthened.
Technical Analysis
Technically, Pfizer is showing initial signs of a stabilising base, which deserves careful attention:
- Momentum Indicators:
- RSI (14 days): 53.6–54.4, signalling a balanced posture—neither overbought nor oversold—indicative of potential to build upward momentum.
- MACD (12,26,9): Marginally positive (0.01 to 0.11), hinting at a nascent bullish crossover and possible trend reversal after sustained declines.
- Support Levels:
- Key levels rest at $22.98, $22.78, and $22.46, with major technical support at $21.53; these have repeatedly attracted buying interest, suggesting the current price is underpinned by institutional flows.
- Resistance:
- Immediate resistance is established near $23.51–$23.83, with upside potential toward $24.03–$25 in the event of renewed buying pressure.
This neutral-to-positive technical construct, supported by robust volume (53.76 million average daily trading) and a five-year beta of 0.50 (lower volatility), sets the stage for a potential bullish reversal. The presence of a well-defined support zone aligns with prudent short- and medium-term entry strategies.
Fundamental Analysis
Pfizer’s fundamental investment case is especially compelling at current valuation levels:
- Revenue and Earnings Quality:
- Last twelve months’ revenue: $62.46bn, maintaining global scale despite post-pandemic cyclical adjustment
- Net profit margin: 12.6%, reflecting healthy profitability amidst sector transition
- Q1 adjusted EPS: $0.92 (beat consensus); full-year adjusted EPS guidance remains solid at $2.80–$3.00
- Valuation:
- TTM P/E ratio stands at 16.99; forward P/E drops to 8.03, representing a clear discount both to historic norms and sector averages
- Price-to-sales (P/S) and price-to-earnings-growth (PEG) metrics imply that expectations are muted, yet do not account for the potential impact of new pipeline launches
- Diversified product portfolio: Spanning vaccines, oncology, rare diseases, cardiovascular, and immunology
- Geographic footprint: Nearly 50% of sales occur outside the US, providing stability versus region-specific regulatory risks—relevant for Irish and wider European exposure
- Solid balance sheet: $17.32bn in cash, supporting R&D and M&A flexibility even in a challenging macro context
- Brand power and innovation: Robust pipeline with a clear focus on new oncology therapies and major initiatives in obesity and metabolic health
This combination of operational breadth, strong capital discipline, and innovation pipeline clearly justifies renewed investor confidence.
Volume and Liquidity
Pfizer consistently demonstrates strong market liquidity, with a three-month average daily volume of 53.76 million shares and a public float of 5.67 billion shares. Such volumes ensure tight bid-ask spreads, reliable price discovery, and the flexibility for both retail and institutional participants to take and adjust positions efficiently.
This liquidity profile is instrumental in maintaining dynamic pricing, fostering confidence in the accuracy of valuation, and reducing slippage for Irish and global investors seeking to scale exposure into periods of heightened volatility or ahead of key corporate events.
Catalysts and Positive Outlook
Several upside catalysts reinforce the constructive outlook for Pfizer:
- Strategic Oncology Expansion: The $6bn licensing agreement with 3SBio and the Seagen acquisition have significantly bolstered Pfizer’s oncology pipeline. The stated ambition to deliver 8 blockbuster cancer therapies by 2030 is already capturing attention.
- Obesity and Metabolic Disorders: Pfizer has made a concentrated push into next-generation obesity treatments—one of the largest growth markets in healthcare—offering the possibility of multi-billion dollar revenues as new data readouts and regulatory milestones approach.
- M&A Capacity: With balance sheet flexibility to support up to $15bn in further value-enhancing acquisitions, Pfizer has the means to supplement organic growth and adapt to emerging market opportunities.
- Cost Optimisation: On track for $4.5bn in annualised savings by end-2025, cost discipline will continue to underpin margin expansion.
- ESG Momentum: Pfizer’s ongoing commitment to ESG (environmental, social, and governance) principles is increasingly aligning the company with investor mandates and index inclusion trends.
From a sector perspective, continued innovation, global demographic support, and increased health system spending post-pandemic point to a favourable setup for established global leaders. Regulatory risk remains, but Pfizer’s diversification and international presence offer a buffer.
Investment Strategies
Pfizer’s current share price and technical setup accommodate a variety of entry strategies:
- Short-term:
- Potential for a tactical bounce from strong support ($22.46–$22.98), particularly if upcoming clinical or partnership newsflow emerges positively.
- Medium-term:
- The period ahead of Q2/Q3 results, anticipated data on obesity drugs, or a new round of pipeline updates presents a classic “buy-the-consolidation” opportunity, especially given the muted valuation and signs of operational and technical bottoming.
- Long-term:
- For investors seeking consistent income and exposure to healthcare’s secular growth, Pfizer offers a 7.33% dividend yield—among the best in the sector—and a market position likely to compound value over time. It is especially relevant for pension and income-focused portfolios, as well as for institutions seeking defensive, low-beta exposure.
Each of these time horizons is supported by both technical and fundamental factors, with an ideal strategic entry near current lows or on any pullback within the established support band.
Is it the Right Time to Buy Pfizer?
In summary, Pfizer presents a potent blend of compelling valuation, high and reliable dividend income, and a fundamentally strengthened long-term outlook. The company’s leadership in oncology and expansion into obesity therapeutics are poised to drive renewed growth, while solid cost controls and a robust pipeline further enhance resilience. Technical signals suggest a bottoming phase with clear upward potential, and sectoral/macro trends continue to favour established players.
For investors positioning ahead of a new healthcare growth cycle, coupled with Pfizer’s unique mix of defensive and innovative attributes, the fundamentals justify renewed interest. The current price level—supported by strong technicals, significant liquidity, and transformative catalysts—may signal the opening of a new bullish phase for this iconic pharma company.
Pfizer stands out as a well-capitalised, globally diversified leader with substantial upside potential: serious investors would do well to consider whether now might be the opportune moment to build exposure ahead of the next leg higher.
How to buy Pfizer stock in IE?
Buying Pfizer shares online is now a straightforward and secure process for retail investors in Ireland. Simply open an account with a regulated online broker, deposit your funds, and you can access Pfizer (PFE) shares in just a few clicks. There are two main methods: direct spot buying (owning the shares outright) or trading Contracts for Difference (CFDs), which allow you to speculate on price movements with leverage. Each approach has its advantages, depending on your financial goals and risk appetite. To help you make an informed choice, a comprehensive broker comparison is available further down the page.
Spot Buying
With a cash (spot) purchase, you buy and own Pfizer shares directly on the NYSE in USD, benefiting from any price increase and eligible dividends. Irish brokers typically charge a fixed commission per trade—often between €4 and €10, which is deducted from your investment.
Important example
Consider this example: If Pfizer shares are trading at $23.45 and EUR/USD is around 1.09, a $1,000 investment allows you to buy about 42 Pfizer shares after accounting for a $5 brokerage fee. ✔️ Gain scenario: If the share price rises by 10% to $25.80, your shares would now be worth $1,100. Result: That’s a +$100 gross gain, or +10% on your investment (not including currency conversion or tax).
Trading via CFD
CFD trading enables you to speculate on Pfizer’s share price without actually owning the stock. Instead, you enter into a contract reflecting the asset’s price change. Fees include the spread (the difference between buy and sell prices) and overnight financing if your position is leveraged and held overnight.
Important example
For example, with a $1,000 stake and 5x leverage, your exposure is $5,000. ✔️ Gain scenario: If Pfizer’s stock price climbs by 8%, your CFD position earns a 40% return (8% × 5), equalling +$400 gross on a $1,000 outlay (excluding trading fees and financing charges).
Final Advice
Before you invest, it’s essential to compare brokers’ fees, trading platforms, and terms—costs and features vary widely between providers. Whether to buy actual Pfizer shares or trade via CFDs depends entirely on your financial objectives, willingness to accept risk, and investment horizon. Use the broker comparison further down the page to choose the best platform for your needs and get started on your investment journey with confidence.
Compare the finest brokers in Ireland and find the best one for you!Compare brokersOur 7 tips for buying Pfizer stock
| f4ca Step | f4dd Specific tip for Pfizer |
|---|---|
| Analyse the market | Assess Pfizer’s stock performance relative to the overall pharmaceutical sector, and consider its strong pipeline in oncology and global diversification when evaluating current price levels. |
| Choose the right trading platform | Opt for a trustworthy Irish or EU-regulated broker that provides easy access to US stocks like Pfizer (PFE) and enables trading in USD or facilitates efficient currency conversion. |
| Define your investment budget | Allocate a clear budget for Pfizer, balancing its defensive profile and high dividend yield (7.33%) with diversification to reduce sector-specific risk. |
| Choose a strategy (short or long term) | For most Irish investors, a long-term approach suits Pfizer’s steady dividend and current repositioning; view periods of weakness as opportunities for gradual accumulation. |
| Monitor news and financial results | Stay updated on Pfizer’s quarterly earnings, new drug approvals, and strategic acquisitions, as these developments can impact share price and dividend outlook. |
| Use risk management tools | Set stop-loss orders and consider taking profits at technical resistance zones; apply position sizing to avoid overexposure to a single company. |
| Sell at the right time | Consider reducing your holding if Pfizer sharply exceeds analyst targets (e.g., above $29), or ahead of potentially negative sector news or regulatory changes affecting pharma stocks. |
The latest news about Pfizer
Pfizer maintains a robust dividend yield of 7.33% and confirms guidance for 2025 revenue and earnings. Pfizer’s high dividend payment is particularly attractive for income-focused investors in Ireland, where the company’s quarterly dividend ($0.43 per share) continues to reward shareholders. On 29 May 2025, Pfizer reaffirmed its annual guidance with expected revenues between $61 and $64 billion and an adjusted EPS target of $2.80–$3.00 for 2025, supporting confidence despite industry challenges. The sustained dividend and clear guidance provide stability for institutional and retail investors in IE, who value predictable returns in their portfolios.
Recent strategic alliances and licensing deals strengthen Pfizer’s oncology pipeline and long-term international positioning. A significant highlight of the past week is the license agreement with 3SBio for cancer drugs, valued at $6 billion, and the partnership with Summit Therapeutics. These agreements exemplify Pfizer’s ambitious oncology strategy, aiming to introduce multiple blockbuster medicines by 2030. For Ireland, where the company has substantial operational and commercial presence—including pharmaceutical manufacturing and distribution—the reinforced pipeline suggests strong future product flow and opportunities for local clinical research partnerships.
First-quarter results show adjusted earnings per share beating forecasts, supported by cost reduction measures. While Q1 2025 revenue dropped 7.8% year-on-year, Pfizer’s adjusted EPS reached $0.92, exceeding analysts’ expectations as cost-savings outpaced revenue pressure from post-pandemic declines. This result reflects positively for Irish investors, as the company’s active cost management underpins margin protection—a key indicator when evaluating multinationals exposed to global price pressures and declining legacy revenue streams.
Technical momentum indicators remain neutral, but the stock demonstrates support stability and upside potential toward analyst targets. Pfizer’s Relative Strength Index (RSI) sits in a neutral range (53.62–54.4), with positive MACD readings, suggesting neither overbought nor oversold conditions. Support holds around $22.98, and resistance is established at $23.51–$24.03, with the consensus analyst target at $29.24 (over 20% upside from current levels). Irish institutional managers—who typically seek steady blue-chip exposures—may view this price stability and potential for gradual recovery as constructive for portfolio allocation.
Pfizer’s strong global footprint, diversified pipeline, and local market integration anchor its strategic outlook in Ireland. With approximately 50% of revenues generated outside the US and a legacy of direct operations in Ireland, Pfizer remains a critical employer and contributor to the Irish life sciences sector. Its commitment to innovation and robust cash reserves ($17.32 billion) position it to capitalize on strategic M&A activity—a factor that could further invigorate its Irish manufacturing base, clinical trials, and supply chain roles. These underlying strengths reinforce Pfizer’s reputation among Irish analysts and institutional stakeholders as a defensive, resilient investment amid ongoing sector transformation.
FAQ
What is the latest dividend for Pfizer stock?
Pfizer currently pays a quarterly dividend of $0.43 per share, with the most recent ex-dividend date on 9 May 2025. That equates to an annual dividend of $1.72, offering an attractive yield relative to the sector average. Pfizer is known for its consistent dividend payments and prioritises shareholder returns as part of its long-standing distribution policy.
What is the forecast for Pfizer stock in 2025, 2026, and 2027?
Based on the current share price of $23.45, the projected values are $30.49 for the end of 2025, $35.18 for the end of 2026, and $46.90 for the end of 2027. These estimations reflect the company’s ongoing strategic investments in oncology and cost savings, combined with a robust innovation pipeline that supports future growth.
Should I sell my Pfizer shares?
Holding onto Pfizer shares may be sensible, considering its defensive profile, strong balance sheet, and resilient dividend track record. The company is navigating post-pandemic challenges with a strengthened pipeline in oncology and a focus on long-term innovation. Its current valuation and global reach suggest potential for mid- to long-term recovery, particularly for those seeking reliable income and exposure to the healthcare sector.
How are dividends and capital gains from Pfizer stock taxed for Irish investors?
For investors in Ireland, dividends from Pfizer are generally subject to US withholding tax (typically 15% if a tax treaty form is filed) and Irish income tax. Capital gains from the sale of Pfizer shares are taxed at the Irish capital gains tax rate, with an annual exemption threshold potentially available. Pfizer stock is not eligible for Irish tax-free savings schemes such as the standard exemption for Irish shares.
What is the latest dividend for Pfizer stock?
Pfizer currently pays a quarterly dividend of $0.43 per share, with the most recent ex-dividend date on 9 May 2025. That equates to an annual dividend of $1.72, offering an attractive yield relative to the sector average. Pfizer is known for its consistent dividend payments and prioritises shareholder returns as part of its long-standing distribution policy.
What is the forecast for Pfizer stock in 2025, 2026, and 2027?
Based on the current share price of $23.45, the projected values are $30.49 for the end of 2025, $35.18 for the end of 2026, and $46.90 for the end of 2027. These estimations reflect the company’s ongoing strategic investments in oncology and cost savings, combined with a robust innovation pipeline that supports future growth.
Should I sell my Pfizer shares?
Holding onto Pfizer shares may be sensible, considering its defensive profile, strong balance sheet, and resilient dividend track record. The company is navigating post-pandemic challenges with a strengthened pipeline in oncology and a focus on long-term innovation. Its current valuation and global reach suggest potential for mid- to long-term recovery, particularly for those seeking reliable income and exposure to the healthcare sector.
How are dividends and capital gains from Pfizer stock taxed for Irish investors?
For investors in Ireland, dividends from Pfizer are generally subject to US withholding tax (typically 15% if a tax treaty form is filed) and Irish income tax. Capital gains from the sale of Pfizer shares are taxed at the Irish capital gains tax rate, with an annual exemption threshold potentially available. Pfizer stock is not eligible for Irish tax-free savings schemes such as the standard exemption for Irish shares.
